Interferon News and Research

RSS

Inhaled steroids reduce ACE2 expression in COPD lungs

A new study by scientists at Imperial College London, University of Newcastle and Prokarium, and published on the preprint server bioRxiv* in June 2020 examines the role played by inhaled corticosteroids (ICS) in the risk of acquisition of COVID-19 infection by COPD patients.

15 Jun 2020

Tuberculosis and polio vaccines may offer temporary protection against SARS-CoV-2

As the world grapples with the coronavirus disease (COVID-19) pandemic, scientists race to develop an effective vaccine to protect against the deadly SARS-CoV-2 virus. While potential vaccines are still being developed and tested, researchers propose that existing vaccines could give the immune system a temporary boost to ward off infection.

14 Jun 2020

Effect of human genes on severity and infectivity of SARS-CoV-2

Now, a new paper published on the preprint server medRxiv* reports the results of an analysis of the association between the genetic variants in the patients and the clinical progression of the disease. The study included 332 patients hospitalized with COVID-19 in a single-center, with widely varying laboratory and clinical features. There were 25, 12, and 17 patients with asymptomatic, mild, and critical disease.

14 Jun 2020

Type III interferons can increase risk of bacterial "superinfections" in the lung, research shows

Interferons and other cytokines produced by the immune system are important defenses against viral infections, but as we have seen in COVID-19, they can also contribute to damaging, potentially life-threatening lung inflammation.

12 Jun 2020

A protein that helps treat viruses can later interfere with lung tissue repair

Researchers at the Francis Crick Institute have found that a protein which is initially helpful in the body’s immune response to a virus, can later interfere with the repair of lung tissue.

12 Jun 2020

Progression and severity of COVID-19 highly dependant on cytokine changes

A new review paper by the researchers from Spain, published in the journal Cytokine & Growth Factor Reviews, demonstrates how changes in the levels of cytokines and other biomolecules are associated with the presence and more serious prognosis of coronavirus disease (COVID-19).

11 Jun 2020

Hydroxychloroquine suppresses 'trained immunity'

A new study published on the preprint server medRxiv in June 2020 shows that the drug hydroxychloroquine (HCQ) suppresses a form of immunity called ‘trained immunity,’ with repercussions for its potential use to treat COVID-19.

11 Jun 2020

Immune modulation can cure severe and often fatal fungal infection in children

In the June 11 issue of the New England Journal of Medicine, a team of UCLA physicians and scientists describes the first case of immune modulation being used to cure a severe and often fatal fungal infection.

11 Jun 2020

Females mount stronger T-cell response to SARS-CoV-2

A new study published on the preprint server medRxiv in June 2020 shows that immune cells, antibody levels, cytokine levels, and viral loads contribute to the sex difference seen in response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

10 Jun 2020

Researchers evaluate survivin expression in neuroendocrine tumors

Volume 11, Issue 23 of @Oncotarget reported that tissue microarrays of 132 patients were stained for survivin using immunohistochemistry and correlated with outcomes.

10 Jun 2020

Unique antiviral action of cholesterol 25-hydroxylase against SARS-CoV-2

A new study by U.S. and Chinese researchers, currently available on the bioRxiv* preprint server, demonstrates how cholesterol 25-hydroxylase and its enzymatic product 25-hydroxycholesterol can inhibit membrane fus

10 Jun 2020

Specific immune signature identified in COVID-19 patients

Researchers at King’s College London and collaborators have identified an “immune signature” that could help researchers better understand coronavirus disease 2019 (COVID-19) and serve as a valuable resource for predicting patient prognosis and informing clinical risk-based stratification.

10 Jun 2020

Immuno-oncology may accelerate the development of treatments for COVID-19

Researchers at Roswell Park Comprehensive Cancer Center have been actively engaged in the effort to develop treatments or other control strategies that can help communities worldwide to address the impacts of the COVID-19 pandemic.

10 Jun 2020

COVID-19 produces lung inflammation in non-human primate experiments

A new study published on the online preprint server bioRxiv in June 2020 reports the successful use of three primate species to model the infection, pathogenesis, and clinical features associated with COVID-19. The research provides useful and immediately available models to test new vaccines and treatments.

9 Jun 2020

Kidney enzyme renalase a potential therapy for severe COVID-19

Researchers from Yale School of Medicine have discovered that a low blood level of an enzyme called renalase is associated with severe coronavirus disease 2019 (COVID-19).

7 Jun 2020

Zinc-finger antiviral protein makes SARS-CoV-2 highly susceptible to interferons

By looking into zinc-finger antiviral proteins (ZAP), a new study from Germany and the United Kingdom (UK) and available on the preprint server bioRxiv suggests that zoonotic transmission of a coronavirus with a specific genetic make-up facilitated the pandemic spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but also its sensitivity to interferons.

7 Jun 2020

Hesperos’ immune system-on-a-chip emulates immune reactions for tissue damage and acute inflammation

Hesperos Inc., pioneers of the Human-on-a-Chip in vitro system, today announced the publication of a new peer-reviewed publication that describes how the company’s technology can be used to investigate immune responses following treatment with biological therapeutics for multi-organ systemic diseases, including cancer, infectious diseases and inflammatory disorders.

4 Jun 2020

A vectored vaccine candidate against SARS-CoV-2

The current pandemic of COVID-19 is caused by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), a betacoronavirus similar to that which caused the SARS-CoV and MERS-CoV earlier. Scientists are pursuing therapeutic drugs and vaccines to counter the relentless spread of the virus, but so far, none has been established to be effective. However, several are in clinical trials in various parts of the world.

2 Jun 2020

Study reveals how a fat cell's immune response worsens obesity

When obesity occurs, a person's own fat cells can set off a complex inflammatory chain reaction that can further disrupt metabolism and weaken immune response--potentially placing people at higher risk of poor outcomes from a variety of diseases and infections, including COVID-19.

2 Jun 2020

Does interferon therapy work in COVID-19?

A new study published on the preprint site medRxiv in May 2020 reports on the efficacy of interferons in treating COVID-19. The research could help evaluate the place of such therapy in the management of this disease.

2 Jun 2020